Comparison Between Efficacy of Daily and Intermittent Low Glycemic Index Therapy Diet

Drug Resistant Epilepsy Clinical Trial

Official title:

Comparison Between Efficacy of Daily and Intermittent Low Glycemic Index Therapy Diet Among Children With Drug Resistant Epilepsy Aged 1-15 Years: an Open Labeled Randomized Controlled Parallel Design Non-inferiority Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03464487
• Other study ID #: Daily vs Intermittent LGIT
• Status: Recruiting
• Phase: N/A
• First received: January 1, 2018
• Last updated: March 7, 2018
• Start date: February 15, 2018
• Est. completion date: January 2019

Study information

• Verified date: March 2018
• Source: All India Institute of Medical Sciences, New Delhi
• Contact: Sheffali Gulati, M.D.
• Phone: 26594679
• Email: sheffaligulati[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Drug resistant epilepsy constitutes about one third of all children diagnosed with epilepsy. Although ketogenic diet is being used for drug resistant epilepsy for almost hundred years, its restrictiveness and adverse effects interferes with its compliance. So less restrictive alternatives like Low Glycemic Index Therapy diet is gradually becoming more popular and its effectiveness is well established. Still the restrictiveness of such monotonous diets is one of the most significant issues for long term maintenance of children on dietary therapy. In this study, we are planning to compare the efficacy of daily and intermittent Low Glycemic Index therapy Diet in children aged 1-15 years with drug resistant epilepsy in a open labelled randomized controlled non-inferiority trial. The children in intermittent LGIT arm will receive the dietary therapy for five days of each week, alternating with a liberal diet on the rest of the two days of the week.

Description:

Drug resistant epilepsy constitutes about one third of all children diagnosed with epilepsy. Although ketogenic diet is being used for drug resistant epilepsy for almost hundred years, its restrictiveness and adverse effects interferes with its compliance. So less restrictive alternatives like Low Glycemic Index Therapy diet is gradually becoming more popular and its effectiveness is well established. Still the restrictiveness of such monotonous diets is one of the most significant issues for long term maintenance of children on dietary therapy. In this study, we are planning to compare the efficacy of daily and intermittent Low Glycemic Index therapy Diet in children aged 1-15 years with drug resistant epilepsy in a open labelled randomized controlled non-inferiority trial. The children in intermittent LGIT arm will receive the dietary therapy for five days of each week, alternating with a liberal diet on the rest of the two days of the week. With a follow up period of 6 months, we are planning to enroll 55 children in each arm. Adverse effect profile in each arm will also be monitored during the study. Also the effect of the dietary therapy on behavior and cognition in each arm will be assessed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 15 Years

Eligibility

Inclusion Criteria:

1. Children aged 1-15 years with drug resistant epilepsy

2. Willing to come for regular follow up

Exclusion Criteria:

1. Surgically remediable cause for drug resistant epilepsy

2. Proven in born error of metabolism except in which dietary therapy for epilepsy is indicated(i.e. pyruvate carboxylase deficiency and GLUT 1 deficiency)

3. Previously received KD, MAD or LGIT

4. Known case of

• Chronic kidney disease

• Chronic liver disease/GI illness

• Chronic heart disease(congenital and acquired)

• Chronic respiratory illness

Related Conditions & MeSH terms

• Drug Resistant Epilepsy
• Epilepsy

Intervention

Dietary Supplement:
• Low Glycemic Index Therapy Diet
Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.

Locations

Country	Name	City	State
India	AIIMS	New Delhi	Delhi

Sponsors (1)

Lead Sponsor	Collaborator
All India Institute of Medical Sciences, New Delhi

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of seizure reduction from baseline at 24 weeks in each arm	Percentage of seizure reduction from baseline at 24 weeks in each arm will be calculated from Daily Seizure Log maintained by parents Percentage of seizure reduction at 24 weeks=x-y/x X 100 Y=Mean daily seizures at 24 weeks as measured over past 4 weeks X=Mean daily seizures at baseline as measured over 4 weeks Seizure log will contain details of number, duration and type of seizures as recorded by parents	Percentage seizure reduction will be calculated for each child in each arm after 24 weeks follow up period is completed and finally mean seizure reduction in each arm will be computed at the end of 24 weeks
Secondary	Proportion of patients with >50% seizure reduction in each dietary arm	Proportion of patients with >50% seizure reduction in each dietary arm will be computed from daily seizure log maintained by parents	At the end of 24 weeks, it will be determined the proportion of children in each arm with >50% reduction in seizure frequency.
Secondary	Change in social quotient with each dietary therapy	Proportion of children with improvement in social quotient at 24 weeks as compared to baseline measured by Vineland Social Maturity scale	Vineland Social Maturity Scale will be done for each child at baseline and at 24 weeks to calculate social quotient at baseline and 24 weeks
Secondary	Proportion of patients with different clinical adverse events in each group	Each participant will be monitored clinically for adverse effects like nausea, vomiting, constipation	Each child will be monitored for adverse effects clinically at 12 weeks and 24 weeks
Secondary	Correlate seizure frequency change at 24 weeks with blood HbA1c levels	Absolute level of blood HbA1c(in percentage) as compared to percentage change in seizure frequency at 3 and 6 months will be computed	Absolute level of HbA1c levels (in percentage) as compared to percentage change in seizure frequency at 3 and 6 months will be computed
Secondary	Correlate seizure frequency change at 24 weeks with blood betahydroxy butyrate levels levels	Blood beta hydroxyl butyrate levels(milimoles/liter) at 12 and 24 weeks as compared to percentage change in seizure frequency will be computed	Blood beta hydroxyl butyrate levels(milimoles/liter) at 12 and 24 weeks as compared to percentage change in seizure frequency will be computed
Secondary	Proportion of patients with different biochemical adverse events in each group	Each participant will be monitored for side effects like anemia, dyslipidemia, deranged liver and renal function tests	Each child will be monitored by certain biochemical investigations like hemoglobin, liver and renal function tests and lipid profile at baseline, at 24 weeks and also in between if clinically indicated